(Q37964574)

26 August 2017

title

Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes (English)

1 reference

26 August 2017

Hee-Doo Yoo

1

1 reference

26 August 2017

Yong-Bok Lee

series ordinal

2

1 reference

26 August 2017

language of work or name

1 reference

1 November 2011

1 reference

Archives of Pharmacal Research

26 August 2017

published in

1 reference

26 August 2017

volume

34

1 reference

26 August 2017

issue

11

1 reference

26 August 2017

page(s)

1817-1828

1 reference

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Role of transport proteins in drug absorption, distribution and excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

The drug efflux-metabolism alliance: biochemical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Bioavailability and bioequivalence: an FDA regulatory overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Improvement and validation of an HPLC method for examining the effects of the MDR1 gene polymorphism on sparfloxacin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Pharmacogenetics of the major polymorphic metabolizing enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Identification and functional characterization of eight CYP3A4 protein variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

ABC Transporters: From Microorganisms to Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Implications of genetic polymorphisms in drug transporters for pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Transporters and xenobiotic disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

21 January 2018

Membrane transporters

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Pharmacogenetics - five decades of therapeutic lessons from genetic diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Interplay of transporters and enzymes in drug and metabolite processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Pharmacogenetics of drug transporters and its impact on the pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Multidrug resistance and the role of P-glycoprotein knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Inheritance and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

CYP2C9 allelic variants: ethnic distribution and functional significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-1104-1

10.1007/S12272-011-1104-1

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference